alexa Real-World Clinical Effectiveness of Liraglutide in Ind
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Real-World Clinical Effectiveness of Liraglutide in Individuals 65 Years and Older with Type 2 Diabetes in the United States

Abhishek Chitnis1*, Michael Ganz1, Mette Hammer2 and Jakob Langer2

1Evidera, Lexington, MA, USA

2Novo Nordisk Inc., Plainsboro, NJ, USA

*Corresponding Author:
Abhishek Chitnis
Senior Research Associate
Retrospective Observational Studies
Evidera 430 Bedford Street, Suite 300
Lexington, MA 02420, USA
Tel: +1 781-960-0256
E-mail: [email protected]

Received date: June 06, 2014; Accepted date: June 27, 2014; Published date: July 04, 2014

Citation: Chitnis A, Ganz M, Hammer M, Langer J (2014) Real-World Clinical Effectiveness of Liraglutide in Individuals 65 Years and Older with Type 2 Diabetes in the United States . J Diabetes Metab 5:403. doi:10.4172/2155-6156.1000403

Copyright: © 2014 Chitnis A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

 

Abstract

Objective: Clinical trials have shown that liraglutide effectively lowers A1C levels and helps manage weight in Type 2 diabetes (T2D). Currently, no studies have solely evaluated the real-world clinical effectiveness of liraglutide in a T2D population of individuals 65 years and older. We examined the clinical effectiveness of liraglutide in individuals aged 65 years and older with T2D 6 and 12 months after starting therapy.
Methods: In this retrospective cohort study we used the General Electric Centricity electronic medical records database. We included individuals with T2D aged 65 years and older who initiated liraglutide at any time from January 1, 2010 to January 31, 2013. Individuals using either insulin or a glucagon-like peptide-1 analogue during 12 months before initiating liraglutide were excluded. Changes in A1C, weight, the proportion of individuals achieving a target A1C<7% and occurrence of severe hypoglycemic events at 6 and 12 months were evaluated.
Results: We identified 517 individuals with T2D who were 65 years and older with A1C>7% at baseline (45 days prior to therapy initiation to 7 days after). Individuals were, on average (standard deviation, SD), 70.6 (4.7) years old, 52.6% were female and 71.6% were white. A1C and weight at baseline were 8.2% (1.0%) and 101.0 (19.7) kg [222.6 (43.3) lbs], respectively. After 6 months A1C decreased by 0.76% (1.1%), weight decreased by 2.9 (5.4) kg [6.4 (11.9) lbs], and 37.1% of the sample achieved the target A1C<7%. Twelve-month outcomes were similar: 0.78% (1.2%) reduction in A1C, 3.1 (5.7) kg [6.8 (12.5) lbs] reduction in weight, and 39.9% achieved A1C<7%. No evidence of severe hypoglycemia was found either at 6 or at 12 months.
Conclusion: Individuals with T2D 65 years and older experienced a significant and sustained reduction in A1C and weight over 6 and 12 months without any occurrence of severe hypoglycemia.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords